Treatment of severely psychotic inpatients with schizophrenia: Olanzapine versus other antipsychotic drugs

International Clinical Psychopharmacology

Volumn 17, Issue 6, 2002, Pages 287-295

  Carrasco, J L ^a   Gutierrez M ^a   Gomez J C ^a   Escobar, Rodrigo ^a   Alvarez E ^a   Canas F ^a   Bobes, J ^a   Gascon J ^a   Gibert, J ^a  

^a NONE   (Spain)

Author keywords

Antipsychotics; Inpatients; Olanzapine; Schizophrenia; Severe psychotic

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE;

ADOLESCENT; ADULT; AGED; AGITATION; AKATHISIA; AKINESIA; ANXIETY; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSARTHRIA; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERSALIVATION; HYPOKINESIA; HYPOTENSION; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; MUSCLE HYPERTONIA; NERVOUSNESS; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREMOR; VISUAL DISORDER; WEIGHT GAIN; XEROSTOMIA;

EID: 0036840032     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200211000-00004     Document Type: Article

References (23)

1. Addonizio G, Alexopoulos GS (1988) Drug-induced dystonia in young and elderly patients. Am J Psychiatry 145:869-871.
2. Alvarez E, Gomez J, Sacristan JA, Bobes J, Cañas F, Carrasco JL, Gascón J (2001) Effectiveness and onset of action of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (EUROPA study). Schizophr Res (Suppl):219.
3. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD (2001) Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 62:231-238.
4. Beasley CM Jr, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S (1996) Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:111-123.
5. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. (1997) Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7:125-137.
6. Breier A, Astracham BM (1984) Characterization of schizophrenic patients who commit suicide. Am J Psychiatry 141:206-209.
7. Breier A (2001) Introduction: A new era in the pharmacotherapy of psychotic disorders. J Clin Psychiatry 62(Suppl. 2):3-5.
8. Brekke JS, Raine A, Ansel M, Lencz T, Bird L (1997) Neuropsychological and psycho-physiological correlates of psychosocial functioning in schizophrenia. Schizophr Bull 23:19-28.
9. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG (1990) Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients [review]. Schizophr Bull 16:477-499.
10. Collaborative Working Group on Clinical Trial Evaluations (1998) Assessing the effects of atypical antipsychotics on negative symptoms [review]. J Clin Psychiatry 59(Suppl. 12):28-34.
11. Gerlach J (1991) New antipsychotics: Classification, efficacy, and adverse effects [review]. Schizophr Bull 17:289-309.
12. Gomez JC, Crawford AM (2001) Superior efficacy of olanzapine over haloperidol: Analysis of patients with schizophrenia from a multicenter international trial. J Clin Psychiatry 62(Suppl. 2):6-11.
13. Gomez JC, Sacristan JA, Hernandez J, Breier A, Ruiz P, Antón C, Fontova E (2000) The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 61:335-343.
14. Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? [review]. Am J Psychiatry 153:321-330.
15. Hamilton SH, Edgell ET, Revicki DA, Breier A (2000) Functional outcomes in schizophrenia: A comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 15:245-255.
16. Karagianis JL, Dawe IC, Thakur A, Begin S, Raskin J, Roychowdhury SM (2001) Rapid tranquilization with olanzapine in acute psychosis: A case series. J Clin Psychiatry 62(Suppl. 2):12-16.
17. Kinon BJ, Roychowdhury SM, Milton DR, Hill AL (2001) Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J Clin Psychiatry 62(Suppl. 2):17-21.
18. Medalia A, Gold JM, Merriam A (1988) The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3:249-271.
19. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 29:21-28.
20. Sacristan JA, Gomez JC, Montejo AL, Vieta E, Gregor K, for the EFESO Study Group (2000) Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study. Clin Therapeut 22:583-599.
21. Tollefson GD, Sanger TM (1997) Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154:466-474.
22. Tollefson GD, Andersen SW (1999) Should we consider mood disturbance in schizophrenia as an important determinant of quality of life? [review]. J Clin Psychiatry 60(Suppl. 5):23-30.
23. Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, Saunders, et al. (2001) Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 158:1149-1151.